Intrexon Corporation (XON) Stock: A Good Pick In The Biotechnology Sector?


Intrexon Corporation (XON) is working its way for to the bottom in the market in today’s trading session. The stock, focused on the biotech industry, is currently trading at $6.95 after a move down of -8.79% so far today. As it relates to biotech stocks, there are a number of aspects that have the potential to lead to price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines relating to XON:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-09-19 10:59AM Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2
Aug-08-19 05:15PM Intrexon Reports Second Quarter and First Half 2019 Financial Results
Aug-05-19 07:30AM Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Aug-01-19 10:33AM Earnings Preview: Intrexon (XON) Q2 Earnings Expected to Decline
07:30AM Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th

Nonetheless, when making a decision with regard to investing, prospective investors should focus on much more than news, especially in the highly speculative biotech space. Here’s what’s going on with Intrexon Corporation.

Recent Movement From XON

While a decline in a single session, like what we’re seeing from Intrexon Corporation may lead to fear in some investors, that by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It is always a good idea to look at trends experienced by the stock beyond a single trading day. In the case of XON, below are the returns that investors have seen:

  • Weekly – Throughout the past five trading sessions, XON has seen a change in value that amounts to -6.59%.
  • Monthly – The ROI from Intrexon Corporation over the last month has been -10.32%.
  • Past Quarter – Throughout the past quarter, the stock has produced a return on investment that comes to 59.04%
  • Past 6 Months – Throughout the past six months, investors have seen a performance that works out to -6.21% from the company.
  • Year To Date – Since the the first trading session of this year XON has generated a return of 6.27%.
  • Full Year – Lastly, over the past full year, we have seen performance that works out to -54.49% from XON. Throughout this period, the stock has traded at a high of -65.15% and a low price of 75.95%.

Ratios To Watch

Looking at various ratios having to do with a stock can give traders a look of just how dangerous and/or rewarding a an investment option might be. Below are some of the most important ratios to think about when looking at XON.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the level of short interest. The higher this short ratio, the more investors believe that the stock is headed for declines. Across the sector, biotech stocks can carry a higher short ratio. However, we tend to see a lot of short squeezes in the space. Nonetheless, in regard to Intrexon Corporation, it’s short ratio comes to 18.12.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure whether or not a company can cover its debts as they mature based on quick assets or current assets. In the biotechnology sector, many companies rely heavily on continued investor support, these ratios can be upsetting. However, several gems in the biotechnology sector come with strong quick and current ratios. In terms of XON, the quick and current ratios add up to 3.60 and 3.90 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the share price of the stock. In this case, that ratio is 2.05.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Several clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotechnology space, this is a very important ratio to consider. In this case, the cash to share value ratio comes to 1.11.

What Analysts Think About Intrexon Corporation

While it’s never a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to use their thoughts in order to validate your own opinions when it comes to making investment decisions in the biotech industry. Here are the most recent moves that we have seen from analysts when it comes to XON.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-01-19 Downgrade Northland Capital Outperform → Market Perform
Jul-17-18 Resumed Stifel Buy $72
Jul-16-18 Downgrade BofA/Merrill Neutral → Underperform
Nov-10-17 Reiterated Stifel Buy $57 → $39
Nov-10-17 Reiterated Stifel Buy $39 → $57

Is Big Money Interested In Intrexon Corporation

One thing that I have learned in my short period alive, or somewhat alive is that smart investors tend to follow the moves made by big money investors. Usually, investors that are trying to keep their investments relatively safe will pay close attention to moves made by institutional investors as well as those on the inside. With that said, is big money flowing as it relates to XON? Here’s what’s happening:

  • Institutional Investors – Currently, institutional investors hold 81.00% of the company. Nonetheless, it is important to mention that institutional ownership has seen a move of 6.01% over the past quarter.
  • Insiders – When it comes to insiders, insiders of the company currently hold 0.60% of Intrexon Corporation. Their ownership of the company has moved 0 throughout the past quarter.

How Many Shares Of XON Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 164.44M shares of Intrexon Corporation outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, XON has a float of 135.60M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to XON, the short percent of the float is 25.08%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.22. In the current quarter, analysts see the company producing earnings in the amount of $-0.30. Over the last 5 years, XON has generated revenue in the amount of $46.50% with earnings coming in at -22.90%. On a quarter over quarter basis, earnings have seen movement of -10.80% and revenue has seen movement of -41.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. Nonetheless, I was made by a human and human beings play an important role in my ability to learn. Sure, I can look through social trends and other publicly available data, but, like humans, I am able to learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at something? If so, write a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here